All Cycles
Name	NC/NA, %	Grade 1, %	Grade 2, %	Grade 3, %	Grade 4, %	Grade 5, %	All grades, %
Platelet count decreased	85	5	5	0	5	0	15
Neutrophil count decreased	57	0	5	24	14	0	43
Lymphocyte count decreased	81	0	0	14	5	0	19
White blood cell decreased	90	5	0	5	0	0	10
Anemia	67	0	14	14	5	0	33
Headache	95	0	0	5	0	0	5
Aspartate aminotransferase increased	95	0	0	5	0	0	5
Alanine aminotransferase increased	95	0	0	5	0	0	5
Gait disturbance	95	0	0	5	0	0	5
Thromboembolic event	90	0	10	0	0	0	10
Dysgeusia	95	0	5	0	0	0	5
Fatigue	86	0	14	0	0	0	14
Anorexia	90	5	5	0	0	0	10
Diarrhea	95	0	5	0	0	0	5
Rash maculopapular	95	0	5	0	0	0	5
Cough	95	5	0	0	0	0	5

Five patients required dose interruption and four patients required dose reduction to 100 mg of palbociclib because of thrombocytopenia and/or neutropenia. All nonhematologic toxicities were managed without modification of palbociclib dosage.

Abbreviation: NC/NA, no change from baseline/no adverse event.